Trending Topic

roflilumast foam
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The FDA recently approved roflumilast 0.3% foam for the treatment of plaque psoriasis of the scalp and body in both adolescents and adults. To better understand how this newly approved therapy fits into clinical practice, what the data show and which patients are likely to benefit, we spoke with Dr Jennifer Soung (Harbor University of California, Los Angeles and Southern California Dermatology, Santa Ana, CA, USA), a key investigator on the phase 3 ARRECTOR trial.

Your Path to Better Medical Knowledge Starts Here – FREE Registration!

Become part of a global network of healthcare professionals enhancing patient outcomes with FREE access to our mobile-friendly medical education platform. Stay up-to-date with the latest scientific advancements, delivered in concise formats, so you can learn anytime, anywhere, at your own pace.

Sign up today and get immediate access to:

  • 1000’s topical and insightful peer-reviewed journal articles

  • 100’s of hours of news, congress highlights, and expert insights from key opinion leaders

  • 10 major therapy areas packed with the latest scientific advances

  • Concise email updates and newsletters so you never miss out

It only takes a minute to register and it’s free (forever) to all healthcare professionals.

touchDERMATOLOGY touchDERMATOLOGY

Register Now!

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

  • Save your progress for video
  • Keep track of your CME credits
  • Add personalised learning notes
  • Receive updates from course leaders and faculty
  • Be the first to hear about new and exciting interactive learning opportunities
Close Popup